Drug Profile
Intracoronary cardiosphere-derived stem cell therapy - Capricor
Alternative Names: CAP-1001; CPI-003; CPI-003 - CapricorLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Capricor
- Developer Capricor Therapeutics; Cedars-Sinai Health System; Johns Hopkins University School of Medicine
- Class Cell therapies; Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Myocardial infarction
Most Recent Events
- 13 May 2019 Discontinued - Phase-I for Myocardial infarction in USA (Intracoronary)
- 31 Dec 2013 No development reported - Phase-I for Myocardial infarction in USA (Intracoronary)
- 21 Nov 2013 Nile Therapeutics has merged with Capricor to form Capricor Therapeutics